Journal of Clinical Oncology
Articles in this Issue
Effectiveness, safety, and patient-reported quality of life with first-line chemotherapy in advanced pancreatic cancer: A nationwide prospective multicenter observational study.
e16388 Background: In advanced pancreatic cancer, mFOLFIRINOX and gemcitabine plus nab-paclitaxel (GnP) are commonly used...
Targeting the NRG1/HER3 axis to overcome therapy resistance in head and neck squamous cell carcinoma: Insights from patient-derived xenografts.
e18056 Background: Epidermal growth factor receptor is frequently overexpressed in head and neck squamous cell carcinoma a...
Implementation of an outpatient multidisciplinary model for care of immune-related adverse events.
e13608 Background: In recognition of the growing burden of acute and chronic immune-related adverse events (irAEs) experie...
Staged dose escalation of adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer: First safety and efficacy data from a Russian cohort.
e12539 Background: This study assessed a staged dose-escalation protocol for adjuvant abemaciclib in routine Russian clini...
Socioeconomic focus in neoadjuvant chemoimmunotherapy: An analysis of pathologic complete response and overall survival in clinical stage II-III NSCLC patients.
8039 Background: In 2022, CheckMate 816 supported neoadjuvant chemoimmunotherapy (CTIO) as standard treatment for clinical...
Genomic biomarkers of primary resistance to anti-EGFR monoclonal antibodies (mAbs) by comprehensive genomic profiling (CGP) in <i>EGFR</i> -amplified (ampl) advanced gastroesophageal adenocarcinoma (aGEA) and correlative analysis from a single-arm study with panitumumab.
4052 Background: EGFR ampl is found in up to 6% of patients with aGEA and accounts for the efficacy of...
Potential effects of TGF-β inhibition on immune resistance by targeting immunosuppressive microenvironment in advanced gastric cancer (AGC): Multi-omics post-hoc analysis of the K-Umbrella-06 trial.
2612 Background: TGF-β signaling promotes immune exclusion by driving fibrosis and hindering T-cell infiltration. We perfo...
Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis.
3592 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent dose-limiting toxicity from oxaliplatin t...
Temporal and demographic trends in hypertension-associated breast cancer mortality in the United States: A CDC WONDER analysis (1999–2020).
e13097 Background: Hypertension is the most common comorbidity among breast cancer survivors and is independently associat...
Evaluating squalene epoxidase association with cholesterol-dependent AKT activation and prognosis in gallbladder cancer.
e16297 Background: Gallbladder cancer (GBC) is a highly aggressive biliary tract tumor with limited therapeutic options an...
<i>CBFB</i> mutations as a predictive biomarker of endocrine therapy benefit in hormone receptor–positive (HR+) breast cancer: Discovery and validation in 3,799 patients.
1089 Background: Endocrine therapy (ET) is the mainstay approach for treating HR+ breast cancer, yet resistance frequently...
Immunotherapy combined with chemotherapy versus chemotherapy alone in advanced pancreatic ductal adenocarcinoma: A real-world retrospective cohort study.
e16437 Background: Conventional chemotherapy remains the first-line standard for advanced pancreatic ductal adenocarcinoma...
Effect of menopausal status on cognitive function and sleep in breast cancer survivors.
e12709 Background: The majority (70-80%) of invasive breast cancers (BC) express estrogen receptors, making endocrine ther...
Patient access to precision medicine: Immune checkpoint inhibitor (ICI) usage in non-small cell lung cancer (NSCLC) and association with income levels across multiple Asian markets.
e13743 Background: Regimens containing ICIs are now considered the recommended treatment option for 1...
Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up.
7526 Background: Linvoseltamab and teclistamab are anti-B-cell maturation antigen (BCMA)×CD3 bispecific antibodies evaluat...
Real-world evidence of the association between primary insomnia and early-onset hormone-related cancers.
11014 Background: Although progress has been made in reducing overall cancer incidence, early-onset cancers have continued...
AYA POWER: An innovative and sustainable virtual model for AYA oncology education.
e21014 Background: Adolescents and young adults (AYAs, ages 15–39) with cancer face care and outcome disparities due to co...
Disparities in breast cancer screening: Insights from an adult female outpatient population in the Northeastern United States.
e13721 Background: Breast cancer (BC) is the most frequently diagnosed cancer among women globally (excluding non-melanoma...
ROCK-2: An ongoing open-label, randomized, multicenter phase 2 study of rocbrutinib versus investigator's choice of therapy in patients with R/R non-GCB DLBCL.
TPS7106 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. Aberrant activation of the...
Identifying patients with human epidermal growth factor receptor 2 (HER2)–low and –ultralow breast cancer (BC): Use of digital, artificial intelligence (AI)–based computational algorithms to assist HER2 scoring by pathologists.
1022 Background: Trastuzumab deruxtecan is approved in HER2-low (IHC 1+ or 2+/ISH negative) or -ultralow (IHC 0 with membr...
Aromatase independent estradiol synthesis in triple-negative breast cancer cells.
e13110 Background: Breast cancer is a leading cause of cancer related deaths in women in the United States. With advanceme...
Reframing access to innovative oncology medicines: The impact of policy and governance reform in a Bismarck-type system in Bosnia and Herzegovina.
1645 Background: Access to innovative oncology medicines is often assumed to depend primarily on available financial resou...
Radiotherapy combined with temozolomide and fluoxetine for newly diagnosed grade 4 glioma: Preliminary report from a single-arm, prospective phase II clinical trial.
e14073 Background: Grade 4 gliomas, including glioblastoma (GBM), are associated with poor prognosis and limited treatment...
Evaluation of autologous tumor-infiltrating lymphocytes (GT201) plus toripalimab in recurrent or metastatic head and neck cancer.
6049 Background: Immune checkpoint inhibitors (ICIs) are the standard treatment for recurrent and/or metastatic (R/M) squa...
The genetic polymorphism underlying immune checkpoint inhibitor–induced endocrine toxicity.
12024 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by enhancing T cell–mediated anti-tu...